Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1CNS 1

Conditions

Neuroblastoma 42Glioblastoma 38Brain Neoplasms 33Glioma 31Central Nervous System Neoplasms 27Gliosarcoma 22Astrocytoma 22Oligodendroglioma 16Medulloblastoma 13Neoplasms 12Rhabdomyosarcoma 7Osteosarcoma 7Recurrence 6Ependymoma 5Diffuse Intrinsic Pontine Glioma 5Sarcoma, Ewing 4Optic Nerve Glioma 4Ganglioneuroblastoma 4Familial ependymoma 4Breast Neoplasms 4Sarcoma 3Rhabdoid Tumor 3Pinealoma 3Pancreatic Neoplasms 3Neurologic Manifestations 3Neuroectodermal Tumors, Primitive, Peripheral 3Colonic Neoplasms 3Choroid Plexus Neoplasms 3Bone Neoplasms 3Wilms Tumor 2

Interventions

lutetium Lu 177 dotatate 1copper dotatate CU-64 1amino-acid, glucose, and electrolyte solution 1PM 01183 1Lutetium-177 1Lutetium 1Irinotecan 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × Irinotecan × CNS × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡